fr

CARMAT continues to build on its momentum in the EFICAS study and reiterates confidence in its 2024 outlook

Update on the feasibility study of the first bioprosthetic artificial heart

Download

Implantation of the CARMAT heart in a 3rd patient at the Georges Pompidou European Hospital

Download

Airbus Group joins the CARMAT Board of Directors

Download

2014 annual results

Download

CARMAT subscribes to a new contingent equity line with Kepler Cheuvreux

Download

CARMAT will benefit from the European SEED program that supports innovative therapy developers seeking reimbursement

Download

The patient who received a CARMAT bioprosthetic heart in Nantes on August 5, 2014 has been discharged home

Download

2015 financial agenda

Download
Top of page